Cargando…

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa

Limited data exist on HIV-1 drug resistance patterns in South Africa following second-line protease-inhibitor containing regimen failure. This study examined drug resistance patterns emerging in 75 HIV-1 infected adults experiencing virologic failure on a second-line regimen containing 2 NRTI and lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallis, Carole L., Mellors, John W., Venter, Willem D. F., Sanne, Ian, Stevens, Wendy
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3066558/ https://www.ncbi.nlm.nih.gov/pubmed/21490784 http://dx.doi.org/10.1155/2011/769627

Ejemplares similares

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Accumulation of Protease Mutations among Patients Failing Second-Line Antiretroviral Therapy and Response to Salvage Therapy in Nigeria
por: Rawizza, Holly E., et al.
Publicado: (2013)

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa
por: Penrose, Kerri J, et al.
Publicado: (2018)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients
por: Han, Yang, et al.
Publicado: (2015)

Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia
por: Limsreng, Setha, et al.
Publicado: (2016)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function
por: Fraichard, Camille, et al.
Publicado: (2021)

Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa
por: Onoya, Dorina, et al.
Publicado: (2017)

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch
por: Eche, Simeon, et al.
Publicado: (2021)

Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance
por: Salata, Robert A., et al.
Publicado: (2023)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART
por: Rawizza, Holly E, et al.
Publicado: (2020)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Geolocalization of HIV-1 subtypes and resistance mutations of patients failing antiretroviral therapy in Salvador – Brazil
por: Filho, Antonio Walter de Oliveira, et al.
Publicado: (2017)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Understanding adherence in virally suppressed and unsuppressed human immunodeficiency virus-positive urban patients on second-line antiretroviral treatment
por: Gumede, Siphamandla B., et al.
Publicado: (2020)

Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir
por: Patel, Mitesh, et al.
Publicado: (2014)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
por: Musana, Hellen, et al.
Publicado: (2021)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
por: Hakim, James G, et al.
Publicado: (2018)

Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa
por: Rossouw, Theresa M., et al.
Publicado: (2015)

Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C
por: Posada-Céspedes, Susana, et al.
Publicado: (2021)

Study protocol: Strengthening understanding of effective adherence strategies for first-line and second-line antiretroviral therapy (ART) in selected rural and urban communities in South Africa
por: Gumede, Siphamandla Bonga, et al.
Publicado: (2021)

High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia
por: Ferradini, Laurent, et al.
Publicado: (2011)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia
por: Jordan, Michael R., et al.
Publicado: (2020)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Treatment outcomes of over 1000 patients on second‐line, protease inhibitor‐based antiretroviral therapy from four public‐sector HIV treatment facilities across Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2016)

Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018)

Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020
por: Alikhani, Ahmad, et al.
Publicado: (2022)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230
por: Vardhanabhuti, Saran, et al.
Publicado: (2016)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4hv3l5r0c4379047rij1agqlf7